TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33423318
Drug: Neutralisation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralisation of IL-10 with recombinant specific blocking antibody
Study: 33141609
Drug: Empagliflozin (SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (SGLT2 inhibitor)
Study: 34563804
Drug: Binaural Sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binaural Sound Therapy (BST)
Study: 34715032
Drug: M5717 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: M5717 (400 mg)
Study: 34715032
Drug: M5717 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: M5717 (800 mg)
Study: 34715032
Drug: M5717 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: M5717 (600 mg)
Study: 34715032
Drug: M5717 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: M5717 (1000 mg)
Study: 37228028
Drug: Subcutaneous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous belimumab 200 mg
Study: 39496199
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges
Study: 32840419
Drug: Accelerated Partial-Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Partial-Breast Irradiation (APBI) - 30 Gy in 5 once-daily fractions
Study: 34547340
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus Saline Solution (LS)
Study: 32891234
Drug: Smaller financial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller financial incentive (10,000 TZS; about US$4.50) for monthly clinic attendance
Study: 32891234
Drug: Larger financial
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger financial incentive (22,500 TZS; about US$10.00) for monthly clinic attendance
Study: 36273186
Drug: Intensity-modulated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated proton therapy (IMPT)
Study: 35818418
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (KRG) capsule
Study: 32726041
Drug: Amoxicillin Capsules
Normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin Capsules (Amoxil)
Study: 34981352
Drug: External facilitation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External facilitation intervention including assessment of local barriers/facilitators, formation of a local implementation team, site visit for action planning and training/education, cross-facility quarterly calls, monthly coaching calls, and consultation.
Study: 33347565
Drug: TU2670 (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU2670 (GnRH antagonist) 20 mg
Study: 33347565
Drug: TU2670 (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU2670 (GnRH antagonist) 40 mg
Study: 33347565
Drug: TU2670 (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU2670 (GnRH antagonist) 80 mg
Study: 33347565
Drug: TU2670 (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU2670 (GnRH antagonist) 160 mg
Study: 36241968
Drug: Penehyclidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine (0.5 mg)
Study: 36241968
Drug: TIVA alone
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA alone (normal saline 5 ml)
Study: 34199001
Drug: Dexmedetomidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2.5 mcg/kg (D)
Study: 34199001
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 mcg/kg and ketamine 1 mg/kg (DK)
Study: 32870726
Drug: EMS diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMS diagnosis of 'seizure-active' with benzodiazepine treatment
Study: 32740328
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure at the Baihui (GV20), Fengchi (GB20), Neiguan (PC6), and Shenmen (HT7) points over a 12-week period
Study: 36367709
Drug: Ticagrelor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (60 mg)
Study: 33945964
Drug: Ankle-related physical
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankle-related physical therapy (control group)
Study: 33880959
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Study: 33880959
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone added to 30 mL of 0.5% ropivacaine
Study: 33880959
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg dexamethasone (control group)
Study: 35612971
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Physician's Choice (TPC) - intravenous doxorubicin 60 mg/m2 every 3 weeks or paclitaxel 80 mg/m2 weekly (3 weeks on/1 week off)
Study: 33884702
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 mcg
Study: 34603045
Drug: TRC150094 150
Normalized name: TRC150094
DrugBank: TRC150094 (DB16046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC150094 150 mg
Study: 33534419
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guided treatment
Study: 38765567
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg once daily
Study: 33250338
Drug: Placebo-controlled (Hidden)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled (Hidden) administration of antidepressant medication for 8 weeks
Study: 35689239
Drug: HLX01 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX01 (1000 mg intravenously on days 1 and 15, followed by 1000 mg on weeks 24 and 26)
Study: 34933984
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention (monthly review of medications, patient education, medication adjustment advice)
Study: 36203568
Drug: 1790GAHB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1790GAHB vaccine (1.5/25 µg)
Study: 36203568
Drug: 1790GAHB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1790GAHB vaccine (6/100 µg)
Study: 36203568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (active comparator vaccines)
Study: 39531231
Drug: Present-Centered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-Centered Therapy (PCT)
Study: 32969946
Drug: Senna (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna (1.0 g)
Study: 32969946
Drug: Magnesium Oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium Oxide (1.5 g)
Study: 37976067
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/d)
Study: 34103405
Drug: Tofacitinib modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib modified-release 11 mg once daily plus methotrexate
Study: 36067506
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement containing Cannabis sativa oil, Boswellia serrata Roxb. Phytosome®, and Zingiber officinale extract
Study: 35943968
Drug: Cognitive Refocusing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Refocusing Treatment for Insomnia (CRT‐I)
Study: 35943968
Drug: Stimulus Control
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus Control Treatment (SCT)
Study: 32917925
Drug: Iron replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron replacement therapy (oral or intravenous)
Study: 32917925
Drug: Biological assessments
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological assessments of iron status
Study: 32669223
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs
Study: 35099988
Drug: Faster intravenous
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster intravenous fluid bolus rates
Study: 33546038
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg/6 h for 2 days, 4 mg/8 h for 2 days, 2 mg/6 h for 2 days, 2 mg/8 h for 2 days, 1 mg/8 h for 2 days, 1 mg/12 h for 2 days)
Study: 35348642
Drug: Adjunct AF
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct AF surgery
Study: 33383112
Drug: Aloe Vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe Vera vaginal cream
Study: 36809193
Drug: E4 15
Normalized name: Ethinylestradiol 15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E4 15 mg
Study: 36399023
Drug: E4 5
Normalized name: Ethinylestradiol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E4 5 mg
Study: 36399023
Drug: E4 10
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: E4 10 mg
Study: 35219377
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg garadacimab
Study: 35219377
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg garadacimab
Study: 33875266
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (50 EU)
Study: 33875266
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (100 EU)
Study: 33875266
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (150 EU)
Study: 616493118
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (0.3 g.kg‐1.d‐1 for 5 days followed by 0.1 g.kg‐1.d‐1 for 23 days)
Study: 35467612
Drug: Positive rumination-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive rumination-based sports prescription (Experimental group)
Study: 33245002
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone and metronidazole
Study: 35509491
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam and syrup (Group S)
Study: 34531205
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2 ?g/kg bolus, 1 ?g/kg/hour infusion up to 3 ?g/kg/hour)
Study: 34531205
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg bolus, intermittent bolus doses up to 2 mg/kg)
Study: 34531205
Drug: Revised regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revised regimen of intravenous fentanyl (2 ?g/kg bolus, 2 ?g/kg/hour infusion up to 5 ?g/kg/hour)
Study: 34531205
Drug: Revised regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revised regimen of intravenous ketamine (1 mg/kg bolus, intermittent bolus doses up to 4 mg/kg)
Study: 34531205
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (revised regimen)
Study: 34531205
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (revised regimen)
Study: 33905680
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of antibiotics in a prehospital setting
Study: 33905680
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of antibiotics
Study: 32955967
Drug: Reproxalap 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks)
Study: 32955967
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks) and prednisolone 1% ophthalmic solution (twice daily taper for 6 weeks)
Study: 34703529
Drug: Haloperidol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2.5 mg/day with methadone (LD group)
Study: 38171633
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) alone
Study: 33788481
Drug: Magnetic beads
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic beads auricular point sticking therapy
Study: 36083488
Drug: Wenshen Jianpi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenshen Jianpi recipe (WJR) combined with antiretroviral therapy (ART)
Study: 33126310
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with pantoprazole 40 mg once daily
Study: 35917650
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 600 mg twice a day
Study: 33518298
Drug: Xylanase supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylanase supplementation (100 mg per kg)
Study: 32979855
Drug: Glucose-with-insulin (GwI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-with-insulin (GwI) infusions
Study: 32979855
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hyperkalaemia within the previous 24 hours
Study: 34403424
Drug: Community-based mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based mass drug administration (MDA) with albendazole
Study: 36094652
Drug: Closed-loop deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop deep brain stimulation (DBS) therapy
Study: 32534645
Drug: Antibiotic shunt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic shunt
Study: 36736921
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy
Study: 32615623
Drug: Telemedical services
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedical services for exclusive remote treatment
Study: 36079092
Drug: Gait Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gait Group (GG) - robotic treatment for gait rehabilitation through an end-effector system
Study: 34792482
Drug: Drug-Eluting Stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stent (DES)
Study: 36072908
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg orally
Study: 32245308
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin per day for 24 weeks
Study: 36094772
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus intravenous methylprednisolone (IVMP) for 7 days
Study: 34047303
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.i.d.
Study: 35263518
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (1.1 GBq) after injections of recombinant human thyrotropin
Study: 33095458
Drug: Laparoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic treatment
Study: 32243402
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine treatment
Study: 33260063
Drug: Genotropin™ (originator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin™ (originator recombinant growth hormone)
Study: 33260063
Drug: Criscy™ (biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Criscy™ (biosimilar recombinant growth hormone)
Study: 32576258
Drug: Extended 6-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended 6-day treatment with artemether-lumefantrine and a single low-dose primaquine
Study: 32576258
Drug: Standard 3-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 3-day treatment with artemether-lumefantrine (control)
Study: 39441580
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg
Study: 39441580
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg
Study: 39331638
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg
Study: 33734057
Drug: RPH-104 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RPH-104 treatment
Study: 35247512
Drug: Leukocyte-poor platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-poor platelet-rich plasma (Lp-PRP) injections (3 injections at the tendon repair site during surgery, at days 7 and 14 after surgery)
Study: 35247512
Drug: Leukocyte-poor platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-poor platelet-rich plasma (Lp-PRP) injections
Study: 33705623
Drug: FAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC plus Simvastatin (40 mg/d orally)
Study: 33705623
Drug: FAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC plus placebo (40 mg/d)
Study: 34018341
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo gel)
Study: 36398439
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus exemestane (25 mg/day)
Study: 35170192
Drug: bremelanotide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bremelanotide (3 times daily for 15 days)
Study: 35170192
Drug: bremelanotide (twice-daily)
Normalized name: clindamycin
DrugBank: Bremelanotide (DB11653)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bremelanotide (twice-daily)
Study: 35170192
Drug: bremelanotide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bremelanotide (3 times daily)
Study: 35893857
Drug: Micronutrient tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient tablets (Tablets)
Study: 36451623
Drug: Light touch
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light touch therapy (LTT) plus repositioning therapy
Study: 33509413
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) implemented by trained staff of opioid treatment programs (OTPs)
Study: 33509413
Drug: New methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: New methods of medication delivery implemented by OTPs
Study: 33838579
Drug: Algorithm Guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm Guided Treatment started with escitalopram (AGT-E)
Study: 33838579
Drug: Algorithm Guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm Guided Treatment started with mirtazapine (AGT-M)
Study: 34343545
Drug: Maxillofacial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillofacial and oral massage (MOM)
Study: 32162741
Drug: Topical red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical red clover oil (20 drops twice a day for 4 weeks)
Study: 32162741
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (control group, 20 drops twice a day for 4 weeks)
Study: 35984574
Drug: Mottling <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mottling < 6 hours and lactate ≥ 2 mmol/L
Study: 38264360
Drug: Dulaglutide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (1.5 mg)
Study: 34797778
Drug: 3-g gluten
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-g gluten challenge
Study: 37429432
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin infusion
Study: 34349116
Drug: Treatment type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type and anxiety symptoms
Study: 34645287
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment plus usual care
Study: 34472698
Drug: Comparators (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparators (placebo, sitagliptin 100 mg, liraglutide 1.8 mg)
Study: 37713133
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg
Study: 32794582
Drug: D/L‐3‐hydroxybutyrate (hyperketotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/L‐3‐hydroxybutyrate (hyperketotic condition)
Study: 32599497
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Protocol (LDP)
Study: 32599497
Drug: Conventional Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Dose Protocol (CDP)
Study: 33709856
Drug: Inhaled Glycopyrronium
Normalized name: glycopyrronium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Glycopyrronium Bromide 6.25 µg BID